Speaker
Dr
James Harvey
(NorthStar Medical Technologies, LLC)
Description
Ac-225 and its daughter Bi-213 have become increasingly important in clinical research for potential treatment of various diseases. The current US production of Ac-225 is limited to about 900 mCi annually from Oak Ridge National Laboratory. While there are limited sources of the stock material used to produce Ac-225, there are options available to meet this need. NorthStar has previously described a high-energy proton spallation of Th-232 approach. This route is capable of supplying daily quantities equivalent to the current annnual supply. This presentation will describe the current development effort that is underway during started in 2017 and continuing toward a goal to continuing development efforts to approach 100mCi+ of Ac-225 per run by the end of 2019, with the ultimate target to achieve sufficient capability in the future to meet market demands.
| Funding Agency | NorthStar funded |
|---|---|
| Email Address | jharvey@northstarnm.com |
| Presentation Type | Contributed Oral |
Primary author
Dr
James Harvey
(NorthStar Medical Technologies, LLC)
